Champions Oncology has announced the full commercial launch of its radiopharmaceutical services platform.
This follows the expansion of the company’s radioactive materials license, the completion of the radiochemistry infrastructure, and the screening of more than 30 PDX models in collaboration with pharmaceutical and biotech partners.
Champions now offers fully-integrated radiopharmaceutical workflows combining in vitro, ex vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company said its platform is differentiated by its bank of patient-derived xenograft (PDX) tumour models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.
“Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology,” said Mike Ritchie, chief commercial officer at Champions Oncology.
“By combining advanced radiochemistry infrastructure with the world’s most deeply characterized PDX bank, we’re helping our clients generate meaningful, translational data that drives confident decision-making earlier in oncology drug development.”
Champions updated radioactive materials license now includes support for ten isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a range of study designs including radioligand therapy (RLT), antibody radionuclide conjugates (ARCs), and theranostic approaches.
“Our goal is to help biopharma partners answer critical questions faster, with data that reflects real tumour biology,” Ritchie said.
“The integration of radionuclide workflows into our PDX platform provides a uniquely powerful preclinical toolset for evaluating biodistribution, tumour targeting, and therapeutic effect.”
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
